Cover Image
市場調查報告書

花生·過敏 : 開發平台分析

Peanut Allergy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251569
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
花生·過敏 : 開發平台分析 Peanut Allergy - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 92 Pages
簡介

花生過敏特別常見於兒童。對花生的過敏反應一般在攝取後數分鐘內發生,症狀分輕微到嚴重幾種。花生過敏的徵兆及症狀有口唇及喉嚨附近出現蕁麻疹和紅腫,發癢、刺痛,或引起像腹瀉,胃痙攣,噁心或嘔吐類的消化器官問題,喉嚨收緊,呼吸急促或發出喘息聲,或流鼻涕等。

本報告提供花生·過敏的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

花生·過敏 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • BioLingus AG
  • BioTech Tools s.a.
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • aldesleukin
  • 花生·過敏的過敏原
  • AR-101
  • ARA-LAMP-Vax
  • DBV-712
  • DN-1017
  • 花生·過敏/氣喘 CYP11A1 抑制劑
  • 呼吸系統· 免疫疾病 PIM-1 激酶抑制劑
  • PER-1080
  • pnut-ASIT
  • 花生·過敏重組蛋白品質
  • 花生·過敏 重組的載體基礎疫苗
  • VTC-064

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8594IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 3, 9 and 5 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Peanut Allergy.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peanut Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Peanut Allergy - Overview
    • Pipeline Products for Peanut Allergy - Comparative Analysis
  • Peanut Allergy - Therapeutics under Development by Companies
  • Peanut Allergy - Therapeutics under Investigation by Universities/Institutes
  • Peanut Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peanut Allergy - Products under Development by Companies
  • Peanut Allergy - Products under Investigation by Universities/Institutes
  • Peanut Allergy - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies, Inc.
    • Aimmune Therapeutics, Inc.
    • Alfacyte Ltd
    • Allergy Therapeutics Plc
    • AnaptysBio, Inc.
    • Aravax Pty Ltd
    • Array BioPharma Inc.
    • ASIT biotech s.a.
    • Astellas Pharma Inc.
    • BioLingus AG
    • DBV Technologies S.A.
    • HAL Allergy BV
    • Sanofi
  • Peanut Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANB-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANN-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-460770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0892 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBV-712 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HALMPE-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peanut Allergy Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PER-1080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pnut-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyvac Peanut - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTC-064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
      • Oct 02, 2016: Immunomic Therapeutics Scientist Presenting at International Society for Vaccines Annual Congress
      • Sep 28, 2016: Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
      • Sep 20, 2016: Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.
      • Aug 18, 2016: Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
      • Aug 01, 2016: DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy
      • Jul 05, 2016: DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer
      • Jun 27, 2016: DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children
      • Jun 21, 2016: Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer
      • Jun 21, 2016: DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere
      • Jun 15, 2016: DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression
      • Jun 13, 2016: Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
      • Jun 07, 2016: Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology Congress 2016
      • Jun 07, 2016: DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board
      • Jun 01, 2016: DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peanut Allergy, H2 2016
  • Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Peanut Allergy - Pipeline by Adverum Biotechnologies, Inc., H2 2016
  • Peanut Allergy - Pipeline by Aimmune Therapeutics, Inc., H2 2016
  • Peanut Allergy - Pipeline by Alfacyte Ltd, H2 2016
  • Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2016
  • Peanut Allergy - Pipeline by AnaptysBio, Inc., H2 2016
  • Peanut Allergy - Pipeline by Aravax Pty Ltd, H2 2016
  • Peanut Allergy - Pipeline by Array BioPharma Inc., H2 2016
  • Peanut Allergy - Pipeline by ASIT biotech s.a., H2 2016
  • Peanut Allergy - Pipeline by Astellas Pharma Inc., H2 2016
  • Peanut Allergy - Pipeline by BioLingus AG, H2 2016
  • Peanut Allergy - Pipeline by DBV Technologies S.A., H2 2016
  • Peanut Allergy - Pipeline by HAL Allergy BV, H2 2016
  • Peanut Allergy - Pipeline by Sanofi, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peanut Allergy - Dormant Projects, H2 2016
  • Peanut Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peanut Allergy, H2 2016
  • Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top